Genome Editing News and Research

RSS

HHMI selects two Boston University medical students to conduct full-time biomedical research

Two medical students from Boston University have been selected by the Howard Hughes Medical Institute to conduct full-time biomedical research in its Medical Research Fellows Program. Joseph Park and Jacqueline Estevez are two of the selected 68 top medical and veterinary students from 37 different schools in the United States to receive this honor.

14 May 2015

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy

29 Apr 2015

ISSCR calls for moratorium on human germline genome editing attempts in clinical practice

In response to an article published by Chinese scientists describing research that used gene editing technologies in human embryos, the International Society for Stem Cell Research has again called for a moratorium on attempts at human clinical germline genome editing while extensive scientific analysis of the potential risks is conducted, along with broad public discussion of the societal and ethical implications.

27 Apr 2015

A beginner’s guide to CRISPR genome editing

In a recent DECODED Online entry, Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, provides an overview of the CRISPR/Cas9 system to scientists looking to enhance their genome modification strategy in model organisms or cell lines.

From Integrated DNA Technologies 14 Apr 2015

USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a significant patent application covering T-Cell receptor-deficient T-Cells which are engineered to express a chimeric antigen receptor.

9 Apr 2015

New approach could help identify novel drug targets to combat lethal fungal infections

By modifying the CRISPR-Cas genome editing system, Whitehead Institute researchers are now able to manipulate Candida albicans' genome systematically--an approach that could help identify novel targets for therapies against this serious pathogen for which there are a limited number of anti-fungal agents.

6 Apr 2015

MDC scientists find solution to increase efficiency of precise genetic modifications

CRISPR-Cas9 is a powerful new tool for editing the genome. For researchers around the world, the CRISPR-Cas9 technique is an exciting innovation because it is faster and cheaper than previous methods. Now, using a molecular trick, Dr. Van Trung Chu and Professor Klaus Rajewsky of the Max Delbrück Center for Molecular Medicine Berlin-Buch and Dr. Ralf Kühn, MDC and Berlin Institute of Health, have found a solution to considerably increase the efficiency of precise genetic modifications by up to eightfold.

30 Mar 2015

ISSCR statement calls for moratorium nuclear genome editing of human germ line

In a statement released yesterday, the International Society for Stem Cell Research called for a moratorium on attempts at clinical application of nuclear genome editing of the human germ line to enable more extensive scientific analysis of the potential risks of genome editing and broader public discussion of the societal and ethical implications.

23 Mar 2015

Virginia Tech researchers use genome-editing method to study lethal disease-carrying animal

Life science researchers at Virginia Tech have accelerated a game-changing technology that's being used to study one of the planet's most lethal disease-carrying animals.

18 Mar 2015

Finding could lead to more effective, less invasive treatment for 'bubble boy' disease

For infants with severe combined immunodeficiency (SCID), something as simple as a common cold or ear infection can be fatal. Born with an incomplete immune system, kids who have SCID--also known as "bubble boy" or "bubble baby" disease--can't fight off even the mildest of germs.

12 Mar 2015

Melbourne researchers develop new genome editing technology to kill blood cancer cells

Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.

12 Mar 2015

IDT’s CRISPR/Cas9 online resource for all your genome editing needs

Integrated DNA Technologies (IDT) has pooled its expertise in genome editing into a free web resource dedicated to providing researchers a hub of information on the very latest in using the CRISPR/Cas9 system.

From Integrated DNA Technologies 9 Mar 2015

VWR, New England Biolabs expand distribution agreement

VWR, a leading, independent provider of laboratory products, services and solutions, announced today the expansion of its distribution agreement with New England Biolabs, Inc.

From New England Biolabs 3 Mar 2015

New strategy may ensure safety of adult epidermal stem cells before performing treatments

A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria.

28 Feb 2015

Researchers develop quality assurance tool for genome editing

A research team at Boston Children's Hospital's Program in Cellular and Molecular Medicine has developed a quality assurance tool for scientists using genome-editing technologies like the increasingly popular CRISPR. The assay, called high throughput genome translocation sequencing (HTGTS), rapidly gauges—for any given gene—these technologies' accuracy and their risk for causing potentially dangerous genomic collateral damage.

9 Feb 2015

FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active.

4 Feb 2015

AstraZeneca announces research collaborations to use genome-editing tool for drug discovery and development

AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas.

30 Jan 2015

HZI professor selected as recipient of 2015 Louis-Jeantet-Prize for Medicine

Prof Emmanuelle Charpentier from the Helmholtz Centre for Infection Research in Braunschweig is one of the two recipients of the 2015 Louis-Jeantet-Prize for Medicine. The prize money of 700,000 Swiss francs is mostly attributed for the continuation of the awardees work.

21 Jan 2015

Johns Hopkins scientists use genome editing technology to alter human stem cells

A powerful “genome editing” technology known as CRISPR has been used by researchers since 2012 to trim, disrupt, replace or add to sequences of an organism’s DNA.

6 Jan 2015

Scientists demonstrate technique for editing genome in sperm-producing adult stem cells

Scientists at Indiana University and colleagues at Stanford and the University of Texas have demonstrated a technique for "editing" the genome in sperm-producing adult stem cells, a result with powerful potential for basic research and for gene therapy.

16 Dec 2014